Advertisement
Best Practice

Best Practice The Best Practice section, which was published until May 2006, summarized the current evidence on an important health intervention. PLOS Medicine no longer publishes this article type in the journal.

See all article types »

Vitamin C for Preventing and Treating the Common Cold

  • Published: June 28, 2005
  • DOI: 10.1371/journal.pmed.0020168

Reader Comments (5)

Post a new comment on this article

Response to the two earlier comments

Posted by plosmedicine on 30 Mar 2009 at 23:44 GMT

Author: Harri Hemila
Position: MD, PhD
Institution: Department of Public Health, University of Helsinki, Helsinki, Finland
E-mail: harri.hemila@helsinki.fi
Additional Authors: Robert M Douglas
Submitted Date: July 28, 2005
Published Date: July 29, 2005
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.

The two responses to our article by Hickey and Roberts, and by Sardi, make the same point, namely that a recent pharmacokinetic study reported that frequent oral intakes of vitamin C would be necessary to elevate plasma ascorbic acid levels to the point where they believe it would have a pharmacological impact. Both authors suggest that the conclusions of our Cochrane review are flawed because all of the placebo-controlled trials that have been carried out so far have used, for both prophylaxis and therapy, one to three times per day of vitamin C ranging from 200 mg daily to as much as 8 grams in a single daily dose.

We have not, as our critics imply, concluded that vitamin C in the doses used in trials reported in the literature has no effect on the common cold. On the contrary, our evidence indicated that in marathon runners and those exposed to high physical and/or cold stress, a substantial prophylactic effect was observed, and that in the general population using regular vitamin C prophylaxis, cold duration was consistently shortened, but the level of shortening was relatively trivial.

We do not consider the vitamin C and the common cold story closed. Nor are we persuaded by the arguments of these three critics that frequent large doses would necessarily result in substantially greater benefits than earlier trials have demonstrated.

We consider that it may be useful to distinguish between a) prophylactic supplementation of people who are in good health and b) therapeutic supplementation of people who have an infection. The kidneys reabsorb essentially all vitamin C when the dietary intake is below 60-100 mg/day and vitamin C level in leukocytes is saturated by approximately 100 mg/day [1], and in this respect we doubt that prophylactic supplementation of healthy people, using doses higher than those in the published trials, might be expected to benefit the general healthy population. On the other hand, there is evidence indicating that common cold infection decreases vitamin C level in leukocytes suggesting changes in vitamin C metabolism [2], and in this respect there seems to be rationale to study the effects of supplementation on people infected with the common cold using even higher doses.

To this point, the claim that these two letters make has not been reported in properly conducted randomized controlled trials of either therapy or prophylaxis. We look forward to incorporating such trials when they have been carried out, in future versions of the Cochrane review. Meanwhile we stand firmly by the conclusions reported in our article.

References
1. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, et al. (1996) Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A 93: 3704-3709.
2. Hume R, Weyers E (1973) Changes in leucocyte ascorbic acid during the common cold. Scott Med J 18: 3-7.

No competing interests declared.